Holen Sie sich die Stockscreener-App
409.47
1.63%
-6.78
Handel nachbörslich:
410.50
1.03
+0.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$416.25
Offen:
$415.61
24-Stunden-Volumen:
1.36M
Relative Volume:
0.84
Marktkapitalisierung:
$104.98B
Einnahmen:
$11.74B
Nettoeinkommen (Verlust:
$3.68B
KGV:
28.86
EPS:
14.1888
Netto-Cashflow:
$3.34B
1W Leistung:
-3.78%
1M Leistung:
-0.20%
6M Leistung:
-5.83%
1J Leistung:
-18.51%
1-Tages-Spanne:
$406.67
$416.27
1-Wochen-Bereich:
$403.16
$430.71
52-Wochen-Spanne:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex reports promising 48-week data for povetacicept in kidney diseases - Investing.com Canada
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week - Markets Financial Content
VRTX: UBS Adjusts Vertex Pharmaceuticals Price Target to $546 | VRTX Stock News - GuruFocus
UBS Adjusts Price Target on Vertex Pharmaceuticals to $546 From $553, Maintains Buy Rating - MarketScreener
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedEarnings Growth Summary & Free Community Supported Trade Ideas - newser.com
Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingRecession Risk & Scalable Portfolio Growth Ideas - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recovery2025 AllTime Highs & Daily Volume Surge Signals - newser.com
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceShort Setup & Capital Efficient Trade Techniques - newser.com
Top Biotech Stocks To Follow TodayNovember 3rd - MarketBeat
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedJuly 2025 Volume & Fast Moving Market Watchlists - newser.com
Nasdaq, Vertex CEOs talk biotech public markets, AI at Boston event - The Business Journals
Agree To Buy Vertex Pharmaceuticals At $290, Earn 6.5% Using Options - Nasdaq
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com
Will Vertex Pharmaceuticals Incorporated bounce back from current supportTake Profit & Verified Swing Trading Watchlist - newser.com
Will Vertex Pharmaceuticals Incorporated stock maintain dividend yieldJuly 2025 Momentum & AI Enhanced Market Trend Forecasts - fcp.pa.gov.br
Promising Biotech Stocks To Watch NowNovember 4th - MarketBeat
Royal Bank Of Canada Issues Pessimistic Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? - Yahoo Finance
Long term hold vs stop loss in Vertex Pharmaceuticals Incorporated2025 Trade Ideas & AI Based Buy/Sell Signal Reports - newser.com
Barclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2025 Earnings Call Transcript - Insider Monkey
Milestone Asset Management LLC Invests $1.13 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bryce Point Capital LLC Purchases 710 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock supported by innovation pipelineWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Huntington National Bank Has $14.88 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma's Painkiller Collapse Sends Shockwaves—But One Drug Could Save It All! - Smartkarma
Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality - Yahoo Finance
Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights - TipRanks
Barclays Maintains Vertex Pharmaceuticals (VRTX) Equal-Weight Recommendation - Nasdaq
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy" - Seeking Alpha
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook - The Globe and Mail
Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat
Why Vertex Skidded Despite Its Beat-And-Raise Quarter - Investor's Business Daily
Committee stocks on the move: Uber and Vertex Pharma - MSN
RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Rating, Lowe - GuruFocus
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Weak Drug Performance - FXDailyReport.Com
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint - sharewise.com
Vertex’s new pain, blood disorder drugs miss Wall Street expectations - BioPharma Dive
Vertex shares slide on reliance on old product - The Pharma Letter
Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration - TipRanks
Analyst Barclays Maintains 'Equal-Weight' for VRTX, Raises PT to $414 | VRTX Stock News - GuruFocus
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio - BioSpace
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $466 From $471, Maintains Market Perform Rating - MarketScreener
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $414 From $408, Maintains Equalweight Rating - MarketScreener
Stifel Adjusts Price Target on Vertex Pharmaceuticals to $445 From $455, Maintains Hold Rating - MarketScreener
VRTX: Stifel Lowers Price Target While Maintaining Hold Rating | - GuruFocus
Vertex touts Journavx launch metrics after novel pain med came up just short of expectations in Q3 - Fierce Pharma
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.65%
3.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):